Alexion (ALXN) Moving Lower Following $1.08B Enobia Acquisition Announcement
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharmaceuticals (Nasdaq: ALXN) shares are continuing lower, though only slightly, following the $1.08 billion deal to acquire Enobia. Shares are down about 0.6 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim said to acquire part of James Hardie's EU business
- Virtu Financial said to explore $3.5B sales of brokerage unit
- SpaceX attempted to acquire AI coding startup Cognition - Bloomberg
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and Acquisitions, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
